Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lymphoma: Mycosis Fungoides

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: Victorson

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma

The purpose of this study is to determine the highest tolerated dose of carfilzomib that can be given by itself or with romidepsin and to evaluate its effects, good and/or bad in treating cutaneous T-cell lymphoma (CTCL).

Status: Accepting New Patients
Principal Investigator: Kuzel

A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

The main purpose of this research is to determine if brentuximab vedotin (SGN-35) improves the outcome of treatment in patients with your type of Cutaneous T-Cell Lymphoma (CTCL) over selected standard therapy (methotrexate or bexarotene). This research will evaluate the proportion of patients achieving an objective response that lasts at least 4 months. Improvement measures also include overall response rate (ORR), lasting at least 4 months, with brentuximab vedotin in patients with CD30+ MF or pcALCL compared to that achieved with therapy in the control arm.

Status: Accepting New Patients
Principal Investigator: Kuzel

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

The purpose of this study is threefold. First, to determine if KW-0761 will work in treating cutaneous T-cell lymphoma (CTCL) that has not responded to other treatments. Second, to evaluate the side effects (good and/or bad) of KW-0761. Third, to compare treatment of CTCL with KW-0761 to treatment with vorinstat.

Status: Accepting New Patients
Principal Investigator: Kuzel

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

last updated: Tue - July 07, 2015 - 08:11 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.